Effect of denosumab for the treatment of postmenoposal osteoporosis in woman caused by the loss of ovarian function due to gynecologic malignancies

Effect of denosumab for the treatment of postmenoposal osteoporosis in woman caused by the loss of ovarian function due to gynecologic malignancies - Effect of denosumab for the treatment of osteoporosis in women with gynecologic malignancies

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017279

Enrollment

Registered

2015-04-25

Start date

2014-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

denosumab

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female patients diagnosed as being osteoporosis after the treatment of gynecologic malignancies

Exclusion criteria

Exclusion criteria: Patients are excluded if being 1. with concomitant use of other agents for osteoporosis 2. with concomitant use of other agents, which potentially affect bone turnover 3. with hypersensitivity to denosumab or other bisphosphonates 4. with hypocalcaemia 5. with severe nephropathy 6. with advanced or metastatic malignancy 7. inappropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Hip BMD and lumber BMD (DXA scan) Bone turnover markers (serum type I collagen cross-linked N-telopeptide)	—

Countries

Japan

Contacts

Public ContactKenjiro Sawada

Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology

daasawada@gyne.med.osaka-u.ac.jp06-6879-3351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026